PI3K/PTEN/Akt/mTOR pathway aberrations and co-incidence of hormone receptors and HER2 in 19,784 diverse solid tumors.

Authors

null

Sherri Z. Millis

Caris Life Sciences, Phoenix, AZ

Sherri Z. Millis , Sadakatsu Ikeda , David Arguello , Rebecca Feldman , Robert Todd Maney , Joanne Xiu , Sandeep K. Reddy , Razelle Kurzrock

Organizations

Caris Life Sciences, Phoenix, AZ, UC San Diego, La Jolla, CA, Caris Life Sci, Phoenix, AZ, Caris Life SCoence, Los Alamitos, CA, UC San Diego Moores Cancer Center, La Jolla, CA

Research Funding

No funding sources reported

Background: Molecular aberrations in the phosphatidylinositol 3-kinase (PI3K) pathway have been documented across cancers, especially PIK3CAmutations and mutation or loss of PTEN. These alterations may be relevant to therapies targeting the PI3K/PTEN/Akt/mTOR signaling pathway. Methods: Molecular profiling was performed on 19,784 tumors ( > 40 cancer types) at a CLIA-certified laboratory. Tests included next generation sequencing (NGS), protein expression (immunohistochemistry), and gene amplification (FISH or CISH). Results: Frequency and type of PIK3CA, AKT1 and PTEN mutations were collated across cancers. Aggregate gene mutation rates (47 genes), protein expression rates (18 proteins), and copy number (5 biomarkers) were measured. Comparison of frequencies and correlations across cancers identified lineage-specific differences, and co-incidences of associated biomarkers, which will be described. Of note, endometrial, breast, cervical, anal squamous cell, and bladder cancers had the highest PIK3CA mutation rate (37%, n = 1600; 31%, n = 2282; 29%, n = 284; 28%, n = 67, 22%, n = 303, respectively). Patterns in AKT1 and PTEN mutation rates differed by cancer, as did PTEN loss - hepatocellular, 57%, prostate, 52%, and endometrial 50% loss. Co-mutation of PTEN and PIK3CA occurred in 1.5% of breast, 0% of prostate, and 12% of endometrial cancers. Of interest, PIK3CA mutations and PTEN loss co-occurred frequently, e.g. 31% of PIK3CAmutated patients also have a PTEN loss. PIK3CA mutations across cancers were distributed 43% in exon 9, 33% in exon 20, and 24% in other exons. Distribution of PIK3CA mutations by cancer type varied and occurred more frequently in the absence of HER2 protein expression or copy number increase (p= 0.0001) and more frequently in the presence of hormone receptor overexpression (androgen receptor (AR), progesterone receptor (PR), and estrogen receptor (ER)) (p= 0.0335). PTEN loss was seen in 27% of patients with and 30% without HER2 overexpression or amplification (p= 0.004). Conclusions: Patterns of biomarker co-alterations across cancers may provide new insights relevant to targeted therapy and may be crucial to optimizing combination treatments.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Tumor Biology

Track

Tumor Biology

Sub Track

Genomic and Epigenomic Biomarkers

Citation

J Clin Oncol 33, 2015 (suppl; abstr 11042)

DOI

10.1200/jco.2015.33.15_suppl.11042

Abstract #

11042

Poster Bd #

255

Abstract Disclosures

Similar Abstracts

First Author: Jianwen Qin

Abstract

2023 ASCO Annual Meeting

Evolution of HER2 scores after neoadjuvant systemic therapy in breast cancer.

First Author: Esther G Chong

Abstract

2021 ASCO Annual Meeting

Breast cancer ER, PR, and HER2 expression variance by germline cancer predisposition genes.

First Author: Grace Wei

First Author: Arunthi Thiagalingam